In a similar manner, a study by Combariza et al. in patients with hematologic malignancies reported that the 30-day mortality reached up to 36% in patients with MASCC scores < 21 and CRP levels > 15 mg/dL, while the rate was 0% among low-risk patients with CRP < 15 mg/dL [11]. This evidence concerns the gene CRP and hematologic disorder.